<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27287635</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1815-7920</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>07</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</Title>
                <ISOAbbreviation>Int J Tuberc Lung Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sputum smear microscopy result: a predictor for drug-resistant tuberculosis?</ArticleTitle>
            <Pagination>
                <MedlinePgn>864-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5588/ijtld.15.0977</ELocationID>
            <Abstract>
                <AbstractText>Until countries establish capacity for continuous surveillance systems, representative surveys of tuberculosis (TB) patients continue to improve our understanding of the burden of drug-resistant TB and help ensure appropriate allocation of resources. Although the available data are limited, the current recommendation of restricting surveys to sputum smear-positive patients is justified, given the greatly simplified logistics and only limited evidence in specific settings of an association between drug resistance and sputum smear status. Nonetheless, the relationship between drug resistance and sputum smear microscopy results may vary according to the setting and population under study. With the increasing availability and use of molecular diagnostics and the drive for universal drug susceptibility testing under the World Health Organization's End TB Strategy, substantially more data on drug resistance in the whole TB patient population should become available in the near future.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dean</LastName>
                    <ForeName>A S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Global TB Programme, World Health Organization, Geneva, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zignol</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Global TB Programme, World Health Organization, Geneva, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lumb</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mycobacterium Reference Laboratory, Microbiology and Infectious Diseases Directorate, South Australia Pathology, Adelaide, South Australia, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lalor</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tuberculosis Section, Public Health England, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Skrahina</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Floyd</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Global TB Programme, World Health Organization, Geneva, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>001</GrantID>
                    <Agency>World Health Organization</Agency>
                    <Country>International</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Int J Tuberc Lung Dis</MedlineTA>
            <NlmUniqueID>9706389</NlmUniqueID>
            <ISSNLinking>1027-3719</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Int J Tuberc Lung Dis. 2016 Jul;20(7):853</RefSource>
                <PMID Version="1">27287631</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001431" MajorTopicYN="Y">Bacteriological Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024901" MajorTopicYN="Y">Drug Resistance, Multiple, Bacterial</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008853" MajorTopicYN="Y">Microscopy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013183" MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018088" MajorTopicYN="N">Tuberculosis, Multidrug-Resistant</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27287635</ArticleId>
            <ArticleId IdType="doi">10.5588/ijtld.15.0977</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>